Abstract
During the current work, we synthesized a new peptide derivative; 4,13-diisopropyl-2,5,12,15-tetraoxo-3,6,11,14-tetraaza-1(3,5)-pyridinacyclopentadecaphane-7-carbohydrazide. The prepared hydrazide was investigated for its in vivo as well as in vitro anticancer effects. Results revealed that this derivative has a great potential against 6 cancerous cell lines. Furthermore, the highest effect was obtained against HT1080 and HeLa cells, where the compound showed 7.4- and 15.1-folds increased activity against them, respectively. Additionally, the compound seems to exert its potential anticancer effect by affecting the kinase enzyme VEGFR-2. Finally, the compound showed promising results when tested in in vivo against prostate cancer developed animal models.